论文部分内容阅读
用单磷酸阿糖腺苷（Ａｒａ·ＡＭＰ）加乙肝疫苗治疗慢乙肝患者４０例，于治疗前、后检测其血清可溶性白细胞介素２受体（ＳＩＬ－２Ｒ）及乙肝病毒ｅ抗原（ＨＢｅＡｇ），并与用一般保肝药物治疗的４０例慢乙肝患者做对照。结果显示，治疗组治疗前、后ＳＩＬ－２Ｒ及ＨＢｅＡｇ均有明显变化，与对照组比较有显著性差异（Ｐ＜０．０５），ＳＩＬ－２Ｒ下降与ＨＢｅＡｇ阴转呈显著正相关性。
Forty patients with chronic hepatitis B were treated with Ara-AMP and Hepatitis B vaccine. The levels of serum soluble interleukin 2 receptor (SIL-2R) and hepatitis B virus e antigen (HBeAg) , And compared with 40 cases of chronic hepatitis B treated with general hepatoprotective drugs. The results showed that both SIL-2R and HBeAg levels in treatment group before and after treatment were significantly different from those in control group (P <0.05). There was a significant positive correlation between SIL-2R decline and HBeAg negative conversion.